39.52 -0.26 (-0.65%)
LLY
| Trade LLY now with |
|
Stock Details
Last Trade:39.52 Change:-0.26 (-0.65%) Prev Close:39.78 Open: 39.74 Days Range:39.46 – 39.83 52 Week Range: 33.46 - 42.03 Volume:31139792 P/E: 10.13EPS:3.90
View AllRecent Alerts 02/10/12
Recent Alert on 02/07/12 at 4:31pm
AMAG Pharmaceuticals (AMAG) Adds Rajiv De Silva and Gino Santini to Board
AMAG Pharmaceuticals (AMAG) Adds Rajiv De Silva and Gino Santini to Board
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced the appointment of Rajiv De Silva and Gino Santini to its board of directors, effective immediately. Mr. De Silva is currently president of Valeant Pharmaceuticals International (NYSE: VRX) and... Read More
Recent Alert on 02/07/12 at 8:24am
European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH
European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH
Recent Alert on 02/07/12 at 8:24am
European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH
European Urology Study Shows Lilly (LLY) Phase III of Cialis and Tamsulosin Improves BPH
Recent Alert on 01/31/12 at 9:41am
Pre-Open Movers 1/31: (PRXL) (MCK) (CLF) Higher; (RSH) (REXX) (ADM) Lower (more...)
Pre-Open Movers 1/31: (PRXL) (MCK) (CLF) Higher; (RSH) (REXX) (ADM) Lower (more...)
Recent Alert on 01/31/12 at 8:03am
Eli Lilly (LLY) Moves Higher Following Q4 Numbers; Zyprexa Expiration Hurts Margins
Eli Lilly (LLY) Moves Higher Following Q4 Numbers; Zyprexa Expiration Hurts Margins
View AllRecent Press Releases
Press Release on 02/09/12 at 9:00am
Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co.
Perception, Opportunity in Volatility - Research & Analysis on VIVUS, Inc. and Eli Lilly & Co.
Press Release on 02/09/12 at 8:00am
Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
Press Release on 02/07/12 at 8:00am
New Study Evaluates Cialis® in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
New Study Evaluates Cialis® in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
View AllRecent SEC Filings
No Recent SEC Filings Available